GBPUSD by UK COVID TimelineThis is the timeline of major COVID related events in the UK and the corresponding chart for GBPUSD. The lower chart is of moving averages of US and UK new COVID cases.
Since the start of COVID and an initial big drop, GBPUSD has seen strength after strength, with a number of significant bottoms coinciding with major events in the UK political landscape.
Put another way, it would appear that several of the government reactions to COVID in the form of Lockdowns and social restrictions have acted as catalysts for significant moves in the Pound.
This can also be seen on the following chart, which is a combination of GBPUSD, GBPCAD AND GBPAUD (these major pairs chosen as they all trade between 1.3-2, giving a roughly similar weighting).
The 1st National Lockdown, introduction of Local Lockdowns and introduction of Hospitality Curfews all created almost perfect short term bottoms for GBP.
We can also see that since the government restrictions have eased - and the subsequent breakout of Omicron variant with little government response - GBP has seen a steady decline.
With new COVID cases reaching back to back all time highs in the UK the general sentiment is that a lockdown, "circuit breaker" or tier system being reintroduced is inevitable. If history tells is anything to go by this is likely to be introduced after Christmas as politicians fear the public backlash if they were to ruin Christmas for families.
Based on this history, if we are to see new strict measures introduced after Christmas, one could potentially view that as a signal to go long GBPUSD or other GBP pair, as the pound has generally responded positively to the introduction of new measures.
Covidvariant
$VIR entry PT 42-44 Long term Target PT 200HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200
CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants
KEY POINTS:
- Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants.
- The companies announced contracts to sell $1 billion worth of sotrovimab to the U.S. government. The FDA has already granted sotrovimab an emergency use authorization to treat mild to moderate Covid infections.
- Though Scangos said the delta variant is “going to be with us for a while,” he added that sotrovimab could likely protect against new variants that emerge.
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
NRXP COVID-19 Vaccine Effectiveness Against Delta VariantNRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant.
Information was released by Israel Institute for Biological Research.
Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines.
I consider this a premium call, the upside i see here is 400%, or the 24usd resistance.
NRXP 52 Week Range 4.07 - 76.99usd. Now the price is 6.75usd.
Is this a buy or not?
Market Cap of only 396.97Mil
Don't miss thisTarget T1: $75
Target T2: $96
Arweave is the world's first blockweave coin -- which is a data storage protocol that enables permanent storage of digital assets such as transactions, smart contracts, Web pages, videos, images, and more, directly on its native blockchain.
#not a financial advice